CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. - Wikidata - awgldk - TriplyDB

CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity.

CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity.

http://www.wikidata.org/entity/Q38315596

about

Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy CYP3A4 and CYP3A5 genotyping by Pyrosequencing Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicine Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests Polymorphisms of CYP2A6 and its practical consequences Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants Comparative analysis of response to selection with three insecticides in the dengue mosquito Aedes aegypti using mRNA sequencing Advances in pharmacogenetics and pharmacogenomics.Cancer therapy and polymorphisms of cytochromes P450.Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment.Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition.Fatal methadone toxicity: potential role of CYP3A4 genetic polymorphism.Pharmacogenetics and antiepileptic drugs.Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man.Cytochrome P450 polymorphisms and response to antipsychotic therapy.Structure-activity relationship for human cytochrome P450 substrates and inhibitors.Pharmacogenetics of the major polymorphic metabolizing enzymes.Pharmacogenomics: marshalling the human genome to individualise drug therapy Pharmacogenomic considerations in drug delivery.Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance.From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy.Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates.Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms.Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation.Cytochrome P450 3A polymorphisms and immunosuppressive drugs.Overview of the pharmacogenetics of HIV therapy.Clinical implications of CYP3A polymorphisms.Cytochrome P450 3A4FNx011B as pharmacogenomic predictor of tacrolimus pharmacokinetics and clinical outcome in the liver transplant recipients Population pharmacokinetics of unbound and total drug concentrations following intravenously administered carbamazepine in elderly and younger adult patients with epilepsy.Past and future applications of CYP450-genetic polymorphisms for biomonitoring of environmental toxicants.Pharmacogenetics of the constitutive androstane receptor.Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.Interindividual variability of methadone response: impact of genetic polymorphism.Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.Pharmacogenomics of CYP3A: considerations for HIV treatment.Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients Gender and interindividual variability in pharmacokinetics.Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer.

P2860

Q24648374-08BD7B70-A269-4122-8AE5-CF55436CC55A Q24810187-AF3878B1-9841-499C-AC33-133B005C57F2 Q26823434-4A06F791-E08A-4320-BDF8-CF0E882DE100 Q27022665-0E01CBDB-8C95-43B9-B16F-BA631B403E32 Q28082746-D3A9CD48-A057-4F19-88D2-083CDCAEA3FC Q28260518-1D616692-A1F9-491B-8C57-CD0113BEEE24 Q28362536-EB310420-A547-4C2C-8C06-C497B7098843 Q28741680-4CF80CF9-1973-4AEF-96D6-F8832E906579 Q33642142-75027A1E-6C5B-4010-B610-4C4683F4F2A1 Q34024117-DD002908-5BA2-4FFB-8536-DA6A2277752B Q34093105-92E0BFF7-F65F-4EF5-9338-305C31E3EAE7 Q34188511-BC585C92-0AE3-4757-B8B1-A88A0FD8A30E Q34278794-143E99F2-E5D8-4FE7-9C39-6ED86D0C3F1A Q34500741-D31FA9C0-764B-4675-B239-BF085B0A309E Q34558112-135529D5-6737-44A5-A240-22917D7A520E Q34604457-239F799C-080C-4640-8345-174E823442F3 Q34612118-C158FC32-5FEF-480C-A0EC-377C0863AB48 Q34627917-0D60F6AC-F7CE-427D-88A1-53907BB3E8AB Q35067187-3DB1F9EB-E19B-44D8-A16E-88063E47FC30 Q35090217-9B3D8836-D100-4B44-90B5-4920521A7034 Q35164676-A8733AE8-4389-422C-9924-65F7ED2DF03D Q35566515-D1776190-B404-404D-8764-AF3324A2FB8A Q35666588-2A566F96-CB1D-4ACA-B58B-EBC504B258F1 Q35825619-1872EDB2-175E-45FC-BDA6-1B75A215AB2D Q35876954-7A40C56E-9409-4E03-8784-5252163ACFD3 Q35952687-17F0AEAC-16F1-4127-AC96-5A891F82E96B Q36050572-DC96DC6C-1C21-4CE8-BBC7-1B4E4293712C Q36389312-30106853-97B7-4A42-BE34-B3AF7A07732D Q36546247-C2C6C044-8DDF-47F8-986C-D75678628182 Q36783322-819747E6-A95E-420A-8576-1884AFE00D18 Q36989348-8386DB2E-04F9-48F3-BEA7-B09161E8A272 Q37000474-7CDB6537-BE48-4099-A82F-88B042479B96 Q37043505-A123AA31-6A7D-446A-AF49-3713E2933D54 Q37074093-F397AE10-CCA1-4632-A060-D7A016929788 Q37142009-C9313463-0D54-4D08-8E96-BE7963EF68CF Q37156272-4D0A50BF-DF25-463E-9F43-17E344BD27EC Q37419542-C88C49DF-AC65-4C93-9D9D-B9F4B3BD82F1 Q37439873-2BC4274B-7693-4877-BCC0-975FD1A62023 Q37550556-2BA81922-599A-4666-BA55-852306A0DFD4 Q37818297-47ACDC75-7009-41A1-A269-823C0345AAE6

P2860

CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity.

http://www.wikidata.org/entity/Q38315596

description

2000 nî lūn-bûn

@nan

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

2000年论文

@zh

2000年论文

@zh-cn

name

CYP3A4 allelic variants with a ...... th altered catalytic activity.

@en

type

label

CYP3A4 allelic variants with a ...... th altered catalytic activity.

@en

prefLabel

CYP3A4 allelic variants with a ...... th altered catalytic activity.

@en

P1433

Q38315596-0568FEBA-BFCE-413F-8F7A-1F803F471051

P1476

Q38315596-72C3793C-3309-4519-8825-DD48BE279240

P2093

Q38315596-04A45171-1767-4F03-ABA4-91E96F5BD048

Q38315596-0611A252-ED3E-49E3-8A93-1F8924BCE1C5

Q38315596-290152F6-91E5-40FA-95E2-749666E0F301

Q38315596-2BAEDD46-C205-48F8-8EA0-5E40E0CDDE93

Q38315596-6C5826C0-CFC9-4683-9248-5EDDAD276BEB

Q38315596-9C745254-8C56-4E17-8104-4D9249AF734C

Q38315596-A413688B-FBA5-4D93-98F8-4F570BE86983

Q38315596-D1607CC3-E63F-4D9F-9282-79E043439789

Q38315596-D1B03706-B7DD-4096-A302-40CA702E1CC0

P304

Q38315596-89E76624-D41C-4585-9E95-3322A95D9961

P31

Q38315596-09BE3009-C7CA-4C98-B893-69CBB048C4AD

P356

Q38315596-CD52D1AB-2DC3-458C-ABA9-06CBCDB26218

P407

Q38315596-4075E039-047E-40BB-B824-C6733A288AB6

P433

Q38315596-2D0B2E15-CF4F-4C95-9A02-598155CCB693

P478

Q38315596-AB17CAD8-3983-4650-BA43-85A1C65FE380

P577

Q38315596-6636C595-4FC8-4BAB-B6F3-A344195B1C9E

P698

Q38315596-EBF54170-C256-4D25-BB99-0CED0337639C

P356

MCP.2000.104391

P1433

Clinical Pharmacology & Therapeutics

P1476

CYP3A4 allelic variants with a ...... th altered catalytic activity.

@en

P2093

Crespi CL

http://www.w3.org/2001/XMLSchema#string

Elizondo G

http://www.w3.org/2001/XMLSchema#string

Gonzalez FJ

http://www.w3.org/2001/XMLSchema#string

Miller VP

http://www.w3.org/2001/XMLSchema#string

Raunio H

http://www.w3.org/2001/XMLSchema#string

Sapone A

http://www.w3.org/2001/XMLSchema#string

Sata F

http://www.w3.org/2001/XMLSchema#string

Stocker P

http://www.w3.org/2001/XMLSchema#string

Zheng W

http://www.w3.org/2001/XMLSchema#string

P304

48-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1067/MCP.2000.104391

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P577

2000-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10668853

http://www.w3.org/2001/XMLSchema#string